Visit Patient Site
Contact Abbott
English
Get Support Kit
EasyToFreeStyle Sign-Up
Get Support Kit

With flash glucose monitoring, it’s easy to see your patients’ hidden patterns and trends.

A painless,1 1-second scan shows a patient’s current glucose reading, an 8-hour history, and a trend arrow indicating where their glucose is heading. By sharing their glucose data with you,* you can see the bigger picture.

Why flash glucose monitoring? 

Patient adherence to SMBG (self-monitored blood glucose) is low

"" ""

Only 1/3 adhere to the frequency of SMBG recommended by their HCP2

"" ""

Almost 2/3 skip SMBG because it is invasive to their lives3

Many patients fail to achieve their optimal glycemic control

A1C <7%  A1C <7% 

<1/4 of patients using insulin achieve their A1C target of <7%4

A1C ≤7%  A1C ≤7% 

1/2 of Canadians with T2D do not achieve their A1C target of ≤7%5

Infrequent glucose testing leads to insufficient glucose data for diabetes treatment decisions

Whether patients meet A1C goals or not, they may experience significant time outside of target range.6

Each of the patients below has an A1C of 7%, yet patients B and C are spending a lot of time outside of target range.

Patient A

Patient A with 7% in A1C - 100% in target range Patient A with 7% in A1C - 100% in target range

Patient B

Patient B with 7% in A1C - 29% above target range, 63% in target range and 8% below target range Patient B with 7% in A1C - 29% above target range, 63% in target range and 8% below target range

Patient C

Patient C with 7% in A1C - 58% above target range, 24% in target range and 18% below target range Patient C with 7% in A1C - 58% above target range, 24% in target range and 18% below target range
Orange color

Above Target Range
(hyperglycemia)

Green color

In Target Range

Red color

Below Target Range
(hypoglycemia)

For illustrative purposes only. Not actual patient data.

International consensus recommendations set clear targets for Time in Range

Recommended time in range for all non-pregnant adults with T1D or T2D6

Target range >70% ; 3.9 mmol/L ;TIME IN RANGE (3.9-10.0 mmol/L)  Target range >70% ; 3.9 mmol/L ;TIME IN RANGE (3.9-10.0 mmol/L) 

For age <25 years with T1D: If A1C goal is 7.5%, the goal for time in range is ~60% (14.4 h/day).
For older/high risk: The goal for time in range is >50% (>12 h/day).
† Includes percentage of values >13.9 mmol/L.
‡ Includes percentage of values <3.0 mmol/L.

The consensus data recommend that adult patients with T1D or T2D spend >70% of their time in range (3.9-10.0 mmol/L).6

Increase time in range. Improve patient outcomes.6

International consensus demonstrates increased time in range results in decreased A1C. An increase in time in range of 10% corresponds to a decrease in A1C of approximately 0.5-0.8%.7

+10% TimeInRange +10% TimeInRange
A1C Down 0.8% A1C Down 0.8%

Decreased time in range is associated with an increased risk of microvascular complications. With every 10% decrease in time in range, there is an increased risk of retinopathy and microalbuminuria.8

64% increased risk of retinopathy 64% increased risk of retinopathy
40% increased risk of microalbuminuria 40% increased risk of microalbuminuria
See the Clinical Evidence

The FreeStyle Libre 2 system reveals a complete picture8§ with a painless,1 1-second scan

Unlike traditional glucose monitoring, flash glucose monitoring provides information about current glucose levels, trends, and the direction and rate of change of glucose.8§

Chart illustrating finger prick checks within a BGM report Chart illustrating finger prick checks within a BGM report
Chart illustrating finger prick checks within a Flash Glucose Monitoring report Chart illustrating finger prick checks within a Flash Glucose Monitoring report
Legend - Finger prick test Legend - Finger prick test

For illustrative purposes only. Not actual patient data.

The use of finger prick testing9§ or A1C alone10§ does not fully reveal glycemic trends. With the FreeStyle Libre 2 system, it’s easy to see your patients’ hidden glucose patterns.8§

See the Clinical Evidence

* The LibreView website is only compatible with certain operating systems and browsers. Please check www.libreview.com for additional information. 

§ Data collected from the FreeStyle Libre system. FreeStyle Libre 2 has the same features as the FreeStyle Libre system, with the addition of optional real-time glucose alarms. Study data are applicable to both products.

 

References:

  1. Haak T, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther 2017;8(1):55-73.
  2. Vincze G, et al. Factors associated with adherence to self-monitoring of blood glucose among persons with diabetes. Diabetes Educ 2004;30(1):112-25.
  3. Wagner J, et al. Invasiveness as a barrier to self-monitoring of blood glucose in diabetes. Diabetes Technol Ther 2005;7(4):612-19. 
  4. Foster N, et al. State of type 1 diabetes management and outcomes from the T1D exchange in 2016-2018. Diabetes Technol Ther 2019;21(2):66-72.
  5. Leiter LA, et al. Type 2 diabetes mellitus management in Canada: is it improving? Can J Diabetes 2013;37(2):82-89.
  6. Battelino T, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 2019;42(8):1593-603.
  7. Beck RW, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes care 2019;42(3):400-05.
  8. Unger J, et al. Practical guidance for using the FreeStyle Libre flash continuous glucose monitoring in primary care. Postgrad Med 2020;132(4):305-13.
  9. Janapala RN, et al. Continuous glucose monitoring versus self-monitoring of blood glucose in type 2 diabetes mellitus: a systematic review with meta-analysis. Cureus 2019;11(9):e5634.
  10. Hirsch IB, et al. Using flash continuous glucose monitoring in primary practice. Clin Diabetes 2019;37(2):150-61. 

 

This site is intended for Canadian Healthcare Professionals only. Visit patient site.

The FreeStyle Libre flash glucose monitoring system is indicated for measuring interstitial fluid glucose levels in adults aged 18 years and older with diabetes mellitus. Always read and follow the label/insert. 

The FreeStyle Libre 2 flash glucose monitoring system is indicated for measuring interstitial fluid glucose levels in people aged 4 years and older with diabetes mellitus. Always read and follow the label/insert.

Why Flash Glucose Monitoring?
About FreeStyle Libre
How to Prescribe
LibreView
Clinic Resources
Educational Events
Abbott. life. to the fullest

© 2023 Abbott
FreeStyle, Libre, and related brand marks are marks of Abbott. Product images are for illustrative purposes only. Other trademarks are the property of their respective owners.
ADC-64590 v1.0

You’re now leaving an Abbott Canada website, a site maintained by Abbott

You are now being redirected to a third-party website not under the control of Abbott. Abbott is not responsible for the contents of such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply the endorsement of the linked site by Abbott.

Do you wish to leave this site?

Disclaimer

MyFreeStyle.ca is a product-specific website intended only for residents of Canada.

If you are a resident of another country, please visit our global directory to locate the appropriate site for your country.